Form 4: Acumen CFO Zuga Receives Significant Equity Grants

Acumen Pharmaceuticals' CFO & Chief Business Officer, Matt Zuga, was granted 99,133 restricted stock units and options to purchase 148,700 shares of common stock.

Summary

• Matt Zuga, CFO & Chief Business Officer of Acumen Pharmaceuticals, Inc. (ABOS), acquired 99,133 shares of common stock through a Restricted Stock Unit (RSU) award on January 16, 2026.
• Each RSU represents a contingent right to receive one share of common stock and will vest in three equal annual installments, commencing one year after the grant date, subject to continuous service.
• Following this transaction, Zuga beneficially owns 309,084 shares of common stock directly.
• Additionally, Zuga was granted employee stock options to purchase 148,700 shares of common stock with an exercise price of $1.89 per share on January 16, 2026.
• These options will vest in 48 equal monthly installments, becoming fully vested on the fourth anniversary of the grant date, subject to continuous service.
• The options have an expiration date of January 16, 2036.
• Following this transaction, Zuga beneficially owns 148,700 derivative securities (options) directly.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates management alignment and retention incentives, which are generally viewed favorably by investors, though it's a routine compensation event.

Positives

• The grant of 99,133 Restricted Stock Units (RSUs) and options for 148,700 shares aligns the CFO's interests with long-term shareholder value.
• Equity compensation incentivizes the CFO to remain with the company and contribute to its growth over the vesting periods.

Negatives

• No direct negatives are identified in this routine equity grant filing.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person's continuous service through each vesting date, meaning the awards could be forfeited if employment ceases.

Future Outlook

The vesting schedules for the RSUs (three equal annual installments starting one year after grant) and stock options (48 equal monthly installments over four years) indicate an expectation of continued service from the CFO and align his incentives with the company's long-term performance.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

Equity grants to executive officers are a standard component of compensation packages across the biotechnology and pharmaceutical industries, designed to attract, retain, and motivate key talent by linking their financial success to the company's stock performance.

Comparison to Industry Standards

• Equity compensation packages for CFOs in the biotechnology sector typically include a mix of restricted stock units and stock options, with vesting schedules designed to promote long-term retention and performance. The specific size of this grant would need to be benchmarked against peer companies of similar market capitalization and development stage to assess its relative competitiveness and alignment with industry norms. Without specific peer data, a direct comparison is not feasible from this filing alone.

Related Party Transactions

• The grants of Restricted Stock Units and employee stock options to Matt Zuga, the CFO & Chief Business Officer, represent compensation-related transactions between the company and an executive officer.

Stakeholder Impact

• Shareholders: The grants aim to align the CFO's financial interests with shareholder value creation, potentially leading to better long-term performance. However, they also represent dilution over time as shares vest.
• Employees: Such grants are part of a broader compensation strategy that can influence morale and retention of key personnel.

Next Steps

• The RSUs will begin vesting one year after the grant date (January 16, 2026) in three equal annual installments.
• The stock options will vest in 48 equal monthly installments, with full vesting on the fourth anniversary of the grant date (January 16, 2026).

Key Dates

Keywords

Acumen Pharmaceuticals, ABOS, Form 4, insider transaction, equity grant, restricted stock unit, RSU, stock option, CFO, executive compensation, beneficial ownership